News

benzinga_article
2025.12.03 16:02
Arrowhead Pharmaceuticals shares are trading higher. Yesterday, the company announced the FDA granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. Also, HC Wainwright raised its price target from $80 to $85 on the stock.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer